Background
==========

There is considerable genomic variability among humans that is not associated with a recognizable clinical phenotype. This variability is evident at both the chromosomal level (as microscopically visible gains or losses of chromosomal bands or regions) \[[@B1]\] and at the single nucleotide level (as single nucleotide polymorphisms (SNPs)) \[[@B2]\]. The gains and losses of sub-microscopic DNA segments larger than 1 kb are termed copy number variants (CNVs) \[[@B3]\]. They represent a newly recognized class of DNA variation, identified as a result of the introduction of comparative genomic hybridization (CGH) array technology that enables the study of variation in the number of copies of specific DNA segments among individuals \[[@B4],[@B5]\]. The widespread presence of CNVs in normal individuals has now been documented using not only array CGH-containing BAC clones \[[@B6],[@B7]\] but also oligonucleotide arrays at high resolution as well SNP data analysis \[[@B8]-[@B12]\] and DNA sequence comparisons between individuals \[[@B13]\].

The discovery of CNVs presents investigators with a number of challenges as CNVs complicate the interpretation of array data and efforts to attribute microdeletions and microduplications identified in individuals with constitutional disorders or in cancerous tissues to the disease processes. The role of CNVs in causing or influencing the susceptibility to disease and genome evolution remains largely unknown. A catalogue of published CNVs can be found in the public database \[[@B14]\], and helps to guide the interpretation of array CGH findings. However, the number and identity of polymorphic loci detected in different studies varies considerably \[[@B15]\], likely because of differences across various array platforms, analytical methods and the populations investigated. In addition, copy number differences for many of the CNVs listed in the above database are not confirmed using secondary independent quantification methods (FISH or quantitative DNA methods). Therefore, further work to identify and characterize CNVs in human populations and confirm copy number variability is essential in order to better understand the significance of CNVs and to determine their role in common disorders.

We studied 27 phenotypically normal individuals and detected 42 different sub-microscopic CNVs using the 1 Mb resolution whole genome array-CGH. We used real-time quantitative PCR (RT-qPCR) and FISH to confirm CNVs. The results of these studies are presented.

Results
=======

1. Array-CGH findings of CNVs in normal subjects
------------------------------------------------

By studying 27 phenotypically normal, healthy individuals (17 females and 10 males; 9 African-American, 9 Hispanic and 9 Caucasian) using commercial array-CGH (Spectral Genomics), 42 different CNVs were identified and further classified into 2 subgroups. Group A contains 26 CNVs which were previously reported in the public database \[[@B14]\], either as an identical clone entry or as part of a reported genomic CNV region. The remaining 16 CNVs in Group B of Table [1](#T1){ref-type="table"} represent novel CNVs. In total, 8 CNVs were observed in two or more individuals; the majority of recurrent CNVs (7/8) belonged to group A. Segmental duplications were found in 8 CNVs (6 in Group A and 2 in Group B). Of the 42 CNVs, only 13 were found to contain genes (N = 28) listed in the OMIM database; 9/28 genes were found in one CNV in Group A (RP11-144O23 mapping to 12p13.2). In addition to genes primarily involved in functions of the human immune or sensory systems, signal transduction and metabolism, genes involved in transcription regulation, neurotransmitter transport, cell proliferation and differentiation or development were also identified (Table [1](#T1){ref-type="table"}).

###### 

Previously reported (A) and novel (B) CNVs

                **Number**   **Cytoband**   **Clone Name**   **Position (Mb)**   **Ethnic origin**   **Duplication**   **Deletion**   **Overlap with segmental duplications**   **Genes on OMIM list**                                                **Biological process**
  ------------- ------------ -------------- ---------------- ------------------- ------------------- ----------------- -------------- ----------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Group A**   1            1p36.13        RP1-163M9\*      16.1                AA                  1                                Yes                                                                                                             
                2            1p13.3         RP11-259N12      103.4               2C, AA, 2H          3                 2              Yes                                       AMY2A, AMY1A, AMY1B, AMY1C                                            Glycogen metabolism
                3            1q42.13        RP5-1016N21      229.7               C, H                                  2              No                                                                                                              
                4            2p12           RP11-345F13      82.8                AA                  1                                No                                                                                                              
                5            2qter          RP5-1011O17      242.9               C, 2H                                 3              Yes                                                                                                             
                6            3q26.3         RP11-114M1       178.8               H                                     1              No                                                                                                              
                7            4q25           RP11-18D18       112.7               H                                     1              No                                                                                                              
                8            6pter          AL035696.14      0.1                 H                                     1              Yes                                                                                                             
                9            6q12           RP11-80L16       67                  AA                                    1              No                                                                                                              
                10           6q24.1         RP1-69B13        146.7               H                                     1              No                                        GRM1                                                                  G-protein mediated signaling, neuronal activities
                11           7pter          RP1-164D18       0.1                 AA                  1                                No                                                                                                              
                12           7p21.1         IIID11           18.8                C                   1                                No                                                                                                              
                13           8p22           RP11-89M16       17.2                C                                     1              No                                        SLC7A2, PDGFRL                                                        Amino acid transport, receptor protein tyrosine kinase signaling pathway
                14           10qter         CTC-261B16       135.2               AA                  1                                No                                                                                                              
                15           11q22.3        RP11-179B7       104.4               AA                                    1              No                                                                                                              
                16           12p13.2        RP11-144O23      10.9                H                   1                                No                                        TAS2R7, TAS2R8, TAS2R9, TAS2R10, PRR4, PRH1, TAS2R13, PRH2, TAS2R14   Taste receptor activity, visual perception, cell adhesion-mediated signaling, immunity and defense
                17           13q21.1        RP11-100C24      56.7                4C, AA, 4H          5                 4              No                                                                                                              
                18           14q12          RP11-125A5       27.6                C, 3H               2                 2              No                                                                                                              
                19           15q11.2        RP11-80H14       20.4                H                   1                                No                                        CYFIP1                                                                Signal transduction, developmental processes
                20           16p11.2        RP11-499D5 \*    33.8                H                                     1              Yes                                                                                                             
                21           16p11.2        RP11-488I20 \*   35.6                H                   1                                No                                                                                                              
                22           16p11.1        RP11-80F22 \*    35.7                C, 2H               3                                No                                                                                                              
                23           17pter         CTB-68F18        0.1                 C                   1                                No                                        RPH3AL                                                                Synaptic transmission
                24           17q24.3        RP11-300G13      68.6                H                                     1              No                                        KCNJ16, KCNJ2                                                         Cation transport, muscle contraction
                25           19p13.2        RP11-79F15       8.8                 C, 2AA, 2H          1                 4              Yes                                       MBD3L1, MUC16                                                         mRNA transcription
                26           19qter         1129-c9          76                  C                   1                                No                                                                                                              
                                                                                                                                                                                                                                                      
  **Group B**   1            2q14.3         RP11-270M20      125.3               C                   1                                No                                        CNTNAP5                                                               Cell adhension-mediated signaling, synaptic transmission
                2            4q28.1         RP11-77P11       128.2               H                                     1              No                                                                                                              
                3            4q31.2         RP11-89E4        145.8               H                   1                                No                                                                                                              
                4            6p24           RP1-103M22       9.5                 H                                     1              No                                                                                                              
                5            7q33           RP11-140I14      134.6               AA                  1                                No                                        CNOT4                                                                 mRNA transcription regulation
                6            10p12.3        RP11-91D9        19.7                H                                     1              No                                                                                                              
                7            12pter         RP11-598F7 \*    0                   C                   1                                No                                        SLC6A12                                                               neurotransmitter transport
                8            13q13.1        RP11-87G1        33                  AA                  1                                No                                                                                                              
                9            19q13.43       F21283           63.7                H                   1                                No                                        MZF1                                                                  regulation of transcription
                10           Xpter          LLNOYCO3M11D2    0                   3C, AA              2                 2              No                                                                                                              
                11           Xp11.3         RP11-252K10      41.7                H                                     1              No                                                                                                              
                12           Xp11.21        RP11-266I3 \*    53.7                AA                  1                                Yes                                                                                                             
                13           Xp11.1         ICRFC100G11100   56.1                C                   1                                No                                                                                                              
                14           Xq21.1         RP11-192B18      84.4                H                                     1              No                                                                                                              
                15           Xq26.2         CTB-45B24        131.4               H                                     1              No                                        PCYT1B, PHF6                                                          Regulation of metabolism and transcription, ovarian follicle development, spermatogenesis
                16           Yq11.2         RP11-91A13 \*    17.7                AA                  1                                Yes                                                                                                             

Note: \* Clone showing multiple sites based on e-FISH.

AA: African American; H: Hispanic; C: Caucasian.

The three clones which showed copy number changes most frequently in our subjects were RP11-259N12 (1p13.3), RP11-100C24 (13q21) and RP11-79F15 (19p13.2), and were found in 5, 9 and 5 individuals respectively.

2. FISH and RT-qPCR analysis of polymorphic clones
--------------------------------------------------

### a) FISH

In order to establish the cellular copy number pattern of known and novel CNVs, we performed FISH analysis of 6 CNVs (Table [2](#T2){ref-type="table"}) in subjects for whom a cell pellet was available. For some clones, copy number changes could be confirmed by FISH, while for others the FISH patterns were discordant with array-CGH results. For example, array analysis of clones RP5-1011O17 at 2q37.3 and RP11-89M16 at 8p22 both showed a deletion upon array analysis, and both were subsequently confirmed by FISH. However, the FISH signal pattern was different for these two clones: clone RP5-1011O17 had a complete loss of one copy, demonstrating a complete deletion while clone RP11-89M16 exhibited a diminished FISH signal on one of the homologs suggestive of a partial deletion (Figure [1](#F1){ref-type="fig"}).

###### 

List of polymorphic BAC clones used for FISH/qPCR analysis in controls.

  **Cytoband**   **Clone name**   **Previously reported**   **Size (kb)**   **Gene(s) contained**   **Overlap with segmental duplications**   **ARRAY**   **FISH**                                               **qPCR**
  -------------- ---------------- ------------------------- --------------- ----------------------- ----------------------------------------- ----------- ------------------------------------------------------ ----------
  2q37.3         RP5-1011O17      Y                         21.8            No                      yes                                       deletion    complete loss of one copy (Fig1)                       C
  13q21.1        RP11-100C24      Y                         129.3           No                      No                                        gain        2 copies (Fig3)                                        NC
                                                                                                                                              loss        2 copies (Fig2)                                        NC
  14q12          RP11-125A5       Y                         186.5           No                      No                                        gain/loss   2 copies (not shown)                                   NT
  2q14.3         RP11-270M20      N                         140.4           No                      No                                        gain        2 copies (not shown)                                   NT
  8p22           RP11-89M16       Y                         176             MTMR7; SLC7A2; PDGFRL   No                                        deletion    partial deletion of one copy (Fig 1)                   C
  12p13.33       RP11-598F7       N                         0.5             SLC6A12                 No                                        gain        multiple sites on non-homologous chromosomes (Fig 4)   NT

C = confirmed

NC = not confirmed

NT = not tested

![**FISH confirmation of deletions detected by array-CGH**. **i**. Deletion of clone RP5-1011O17 (2q27.3) as demonstrated by a single signal in both metaphase chromosomes (arrowhead) (i) and interphase cells (ii). Partial deletion of clone RP11-89M16 (8p22) is seen as a diminished signal on one of the homologues (iii). A control probe at 8qter, RP11-17M8, was used to eliminate difference in signal intensities due to artifacts. One of the signals on 8p22 was consistently smaller (arrow) than any of the 3 remaining signals on the two chromosome 8 homologues.](1471-2164-8-167-1){#F1}

Conversely, FISH analysis of clone RP11-100C24 (13q21.1) showed consistent normal signal patterns (2 copies/cell) in multiple subjects regardless of whether the clone was seen as a loss (Figure [2](#F2){ref-type="fig"}) or gain (Figure [3](#F3){ref-type="fig"}) on array analysis. Gains of clones RP11-125A5 and RP11-270M20 could not be confirmed by FISH (Table [2](#T2){ref-type="table"}). Finally, gain of the clone RP11-598F7 was seen as multiple signals mapping to several chromosomes, demonstrating the presence of homologous sequences within this clone in several regions of the genome (Figure [4](#F4){ref-type="fig"}). This observation was also confirmed by the *in silico*eFISH simulation tool \[[@B16]\].

![**Array and FISH analysis of BAC clone RP11-100C24 (loss)**. **(i)**The array detected deletion of RP11-100C24 could not be confirmed in interphase (ii) and metaphase cells by FISH (iii). The details of profile interpretation are described in Tyson et al \[26\]. Briefly, deletion of a clone was considered if the red and the blue array profiles show separation for that clone and the red profile is above the line corresponding to the value of 1. On the other hand, if the blue array profile is above the line corresponding to the value of 1, a gain for the clone is considered.](1471-2164-8-167-2){#F2}

![**Array and FISH analysis of BAC clone RP11-100C24 (gain)**. **(i)**The array detected gain of RP11-100C24 could not be confirmed in interphase (ii) and metaphase cells by FISH (iii).](1471-2164-8-167-3){#F3}

![**Duplication of clone RP11-598F7 in a normal subject**. Gain of a terminal clone from 12p on the array is indicated with an arrow (i). FISH probe for this clone hybridizes to multiple non-homologous chromosomes (chromosome 12-arrow; chromosome 20-arrowhead, ii)](1471-2164-8-167-4){#F4}

### b) RT-qPCR and FISH comparisons

RT-qPCR analysis was performed for 3/6 clones tested by FISH in order to confirm the array results and to help resolve the array and FISH discrepancies (Table [2](#T2){ref-type="table"}). Comparable results between FISH and RT-qPCR were obtained for all 3 clones tested by both methods -- i.e. deletions of RP11-89M16 and PR5-1011O17 were confirmed by RT-qPCR and the lack of copy number change (both gain and loss) for RP11-100C24 as seen by FISH was also noted by RT-qPCR.

Discussion
==========

Our study of 27 normal subjects revealed a total of 42 CNVs: 26 previously described CNVs \[[@B14]\] and 16 (38%) novel CNVs. A higher number of known than novel CNVs showed recurrence in the subjects tested (7/8 recurrent clones were previously described -Table [1](#T1){ref-type="table"}). Similarly, evidence of segmental duplications was found in 6/8 previously described CNVs. This confirms the observation that recurring CNVs are more prevalent in the human population, and tend to be associated with segmental duplications \[[@B7]\], while our novel CNVs are possibly less frequent and individual specific.

The number of CNVs detected in our controls is comparable to the number obtained by other investigators using the same commercial array-CGH and cut-off levels \[[@B17]-[@B19]\]. However, the number is significantly smaller than that observed by Iafrate et al \[[@B6]\] who reported 255 CNVs in 59 individuals. Although they used the same array-CGH platform, a different dynamic website-based analytical method was applied, instead of our fixed cut-off levels of 1.2 for duplications and 0.8 for deletions, suggesting that the analytical method used plays a significant role in the number of apparent CNVs detected among individuals. Recently, a number of studies addressed the question of global genomic variation using different approaches including tiling BAC array \[[@B7],[@B12],[@B20]\], SNP polymorphisms and oligo arrays \[[@B9]-[@B11]\]. The number of CNVs and chromosomal regions affected varied among studies even when the same array platform was used. For example, the BAC tiling arrays detected 3654 autosomal segmental CNVs in 95 controls \[[@B7]\], 913 CNVs in 270 controls \[[@B12]\] and 258 CNVs in 100 individuals with intellectual disability and their phenotypically normal parents \[[@B20]\]. The differences in the populations studied may have contributed to the observed discrepancies, however, even when the same individuals were examined using a different approach (BAC array vs. SNPs) less than half (43%) of the CNVs were detected on both platforms \[[@B12]\]. It is now evident that none of the existing technologies can capture all human variation.

One of the pre-requisites for understanding global human variation is the confirmation of CNVs using alternative methods. Their recurrence and presence as detected using different platforms supports that these are true differences among individuals. However, a large number of CNVs are still \"unique\", i.e. specific for a control subject/family or study. Independent quantification methods such as FISH or RT-qPCR should ideally be performed on many CNVs, particularly those appearing in one individual, as these are the most likely ones to be false positives \[[@B7]\]. Considering the large number of CNVs reported (\>6000 entries in the database of human variation) the number of validated CNVs using independent quantification methods such as RT-qPCR or FISH is still proportionally very small due to the time consuming or limited throughput of single locus analysis. For example, in two recent larger studies reporting a total of \>5000 CNVs, less than 300 CNVs were validated using quantification methods \[[@B7],[@B12]\]. Using FISH we have confirmed array-detected copy number changes of 3/6 selected CNVs (Table [2](#T2){ref-type="table"}), while for 3/6 CNVs a normal two signal FISH pattern was seen. We tested two FISH-confirmed CNVs using RT-qPCR, one partially and one fully deleted (RP11-89M16 and RP5-1011O17, respectively), and observed concordance between all 3 methods (array-CGH, FISH and RT-qPCR). As two of the three FISH non-confirmed CNVs (RP11-125A5 and RP11-100C24) are recognized as being very common and recurrent on multiple platforms \[[@B6],[@B12]\], we further evaluated RP11-100C24 using RT-qPCR but failed to achieve confirmation of both gain and loss. It is possible that this CNV is composed of tightly packed repeats which can be discerned only by fiber FISH, as noted for clone RP11-259N12 from chromosome 1 \[[@B6]\]. Additional cause of the array-CGH vs. FISH/RT-qPCR discrepancy may be due to the fact that array-CGH assays evaluate the relative ratio of segmental DNA copy number in the test DNA vs. reference DNA, and do not provide an absolute number of copies, as explained in Figure [5](#F5){ref-type="fig"}.

![**Correlation of FISH patterns with array detected copy number variability**. The discordant results between the array and FISH/RT-qPCR findings may be due to the fact that array CGH uses the relative ratio of segmental DNA copy number in the test DNA and the reference DNA, the latter being a pool of genomic DNA from several different normal individuals. The copy number of a specific clone in the reference DNA pool determines the outcome of an array analysis (typical gain (i) and loss (ii) on the array and FISH are shown in Figure 5A). For clones with a very variable copy number, a loss on the array may simply be the result of fewer copies in the test individual compared to the pool of reference DNA (Figure 5B), and if the number of copies in the test individual is 2, confirmation by any of the methods (FISH or qPCR) may not be possible. Conversely, the gain on the array is the result of the presence of more copies of the specific DNA segment in the test DNA compared to the reference (Figure 5C). If the gain occurred as a tandem duplication (or multiplication) of the DNA segment, its detection may not be possible by FISH due to limited resolution. Alternatively, if the gain involved only some sections of the DNA segment, then it may not be detectable by RT-qPCR as typically only a small number of short sequences within non-repeated DNA segments within each region are used for analysis.](1471-2164-8-167-5){#F5}

The information on new CNVs is expanding dramatically, and cataloguing clones for which independent quantification is performed are desirable, as only detailed analysis of a large number of CNVs will help better understand their basic structure, DNA content and reasons for variability. Currently, the significance of CNVs remains puzzling, as many of these genomic regions contain genes and coding sequences associated with known genetic disorders \[[@B6],[@B8],[@B21]\]. In our subjects 13/42 different CNVs were associated with OMIM genes; the number was usually not higher than 2 genes/CNV, except for CNV RP11-144O23 which had 9 genes involved in sensory perception, cell adhesion-mediated signaling, immune and defense processes (Table [1A](#T1){ref-type="table"}). This clone was noted in one of our Hispanic individuals and was reported as one of the more divergent clones in the 4 populations reported by Redon et al \[[@B12]\]. Many of the genes in CNVs are described as \"environmental sensor genes\" and are associated with mechanisms mediating immune responsiveness (defensin, interferon regulatory factor 4, etc.), cellular metabolism (cytochrome P450 genes and carboxyesterase gene families), and membrane surface interactions (Rhesus blood group gene families, melanoma antigen gene). It is now established that the copy number variability of some genes can influence susceptibility to some diseases \[[@B22],[@B23]\]. For example, it has been reported that people with fewer copy numbers of *CCL3L1*, a gene involved in immunity, are more susceptible to HIV infection \[[@B22]\]. The extent of associations of CNVs with disease susceptibility will become clearer as we learn more about the distribution of well characterized CNVs in individuals whose health and medical histories are fully evaluated.

Conclusion
==========

Submicroscopic CNVs are a common form of human genomic variation, which can be readily identified by array-CGH technology in phenotypically normal individuals. The number of CNVs detected in each study is influenced by several factors, especially the array platform and method of analysis. Our results confirm the wide distribution of CNVs in three different ethnic populations and expand the number of recognized CNVs. Cataloguing of confirmed CNVs, quantified using independent methods, would facilitate their interpretation and understanding of their significance in the future.

Methods
=======

Subjects
--------

Normal controls: A total of 27 normal individuals were studied. Nine Caucasian volunteers were recruited for the study and their DNA extracted and chromosomes obtained using routine methodology. Eighteen previously banked DNA samples from African-American and Hispanic individuals were also examined. All samples were anonymized for all personal identifiers.

Array CGH
---------

Array-CGH methods were performed as previously described \[[@B24]\]. Briefly, we used the commercially available genomic DNA array comprising 2,600 BAC clones with an average of 1 Mb resolution throughout the human genome (Spectral Genomics™, Houston, TX). The list of clones on this array can be obtained from website \[[@B25]\]. Genomic DNA from the tested subjects was extracted from peripheral venous blood using Puregene DNA Isolation Kit (Gentra Systems Inc., Minneapolis, MN, USA) according to the manufacturer\'s protocol. The reference DNA was purchased from Promega and represents a pool of genomic DNA from four normal control samples. Both forward (test DNA labeled with Cy3, reference DNA labeled with Cy5) and reverse labeling experiments (test DNA labeled with Cy5, reference DNA labeled with Cy3) were performed for each patient. Following hybridization, slides were scanned on a GENEPIX 4000B scanner (Axon Instruments, Union City, CA) and the 16-bit TIFF images captured using GENEPIX Pro 4.0 software. The images were analyzed using SPECTRALWARE TM BAC Array Analysis Software v2.0 (Spectral Genomics) as described previously \[[@B24]\]. In all cases except one, the test and reference DNA were sex matched. For the sex unmatched case, the clones on the X and Y chromosome were not considered. We have used cut-off values of 1.2 for gain and 0.8 for loss as determined previously by ourselves and others \[[@B17]-[@B19],[@B24]\]. In addition, we performed one self hybridization array experiment to detect the number of artifactual gains/losses. In this latter experiment, no copy number changes were observed.

The database of human genomic variants \[[@B14]\] was used to check if the CNV has been previously reported and the presence of segmental duplications within it. The gene content strictly within the CNV was established using the same database as well as the NCBI and UCSC databases (build 35.1).

FISH
----

BAC DNA clones that were identified to show copy number change by array-CGH were purchased from Spectral Genomics (Houston, TX), labeled directly by Spectrum Red or Green (Vysis, Downers Grove, IL) using nick translation and hybridized to metaphase chromosomes and interphase nuclei from human peripheral blood lymphocytes according to the manufacturer\'s instructions and as previously published \[[@B26]\]. Slides were viewed on a Zeiss Axioplan 2 fluorescence microscope and images captured using Macprobe software (Applied Imaging, Santa Clara, CA). For each FISH probe, at least 10 metaphase cells and 50--100 interphase nuclei were counted blindly by two observers. The normal pattern of FISH signal distribution was determined using 3 single copy BAC clones (RP1-3K23 on 7q36.3, RP11-58F7 on 7q36.3 and RP11-143E20 on Xp22.31), which showed no copy number changes in any of the control individuals on array analysis. The normal signal counts in 3 control experiments showed that most of the interphase nuclei had a concordant 1:1 and 2:2 signal pattern, while a discrepant signal number (mainly 1:2) was seen in around 20% of cells (due to asynchronous replication and/or FISH artifacts). This signal pattern is consistent with other publications using FISH with single copy clones \[[@B8]\].

Based on these values and our experience in FISH confirmation of microduplications \[[@B24]\], the predominance of cells (\>50%) with a pattern different than 1:1 or 2:2 was determined arbitrarily to represent true copy number variability. Increase of DNA clone copy number was considered if a discrepant number of FISH signals (eg.1:2; 2:3), or more than 4 signals/interphase nucleus were predominantly observed (\>50 % cells). A loss of the DNA clone sequences was considered if \>50% interphase nuclei/metaphase chromosomes had one signal, or one of the signals was consistently fainter than the other.

RT-qPCR
-------

All array-detected deletions and duplications are confirmed using real-time quantitative PCR (RT-qPCR) with SYBR Green I detection \[[@B27]\], using 3 non-polymorphic markers evenly distributed within the deleted/duplicated clones. To ensure optimal primer design, DNA sequences spanning the target clones were retrieved from on-line sequence databases and repositories, and checked for the presence of repeated DNA sequences using RepeatMasker \[[@B28]\]. This allowed us to identify unique sequences within the target regions, whilst avoiding DNA segments with complex repetitive elements. Primer sets were designed within these unique sequences using the Primer Express v 3.0 program (Applied Biosystems). Primers were checked for any potential SNPs located within them using online SNP blasting.

Real-time detection of PCR products was performed using the ABI Prism 7900HT system which allows one to see the threshold cycle (C~T~) during the exponential phase of amplification (i.e. when none of the PCR reagents are limiting), and quantify each allele, such that a single allele at a test locus in a person with a deletion would show less amplification (i.e. \~50%) than in a person with two copies of that allele. We compared the amplification of test marker loci (i.e. within the region suspected of being deleted or duplicated) with that of non-contiguous markers (i.e. from another chromosomal region) performed at the same time. The list of primers used is shown in Table [3](#T3){ref-type="table"}.

###### 

Primers used in RT-qPCR.

  ---------------------------------------------------------------------------------------------------------------
  **Cytoband**   **Clone name**   **Primer name**   **Forward primer (5\'-3\')**   **Reverse Primer (5\'-3\')**
  -------------- ---------------- ----------------- ------------------------------ ------------------------------
  2q37.3         RP5-1011O17      RP5-1011O17-A\    AAATGGTGACTCTTGTGAATTTGGT\     GGGAAGCTGTGGCCAAAA\
                                  RP5-1011O17-B\    GGGAAGGTGGGTGGCTACA\           CAAGCAGGCCTTGGTAACACA\
                                  RP5-1011O17-C     ACACTGATGAAGGTTTTCCTTGTG       GGCAGCACTGAACTACAGCAGTT

  13q21.1        RP11-100C24      RP11-100C24-A\    CCACCTCCCAACTCTGTGTGT\         CCCTCCAGAGATAGCACGTTCT\
                                  RP11-100C24-B\    CTGCTTTATGGTGCCTTTTGC\         GTCAGAGAGGACTGCGGAAACT\
                                  RP11-100C24-C     TGTTTTGGCTTTCTGGCAGTT          CAAAGGCAGGAGGCTGTTCT

  8p22           RP11-89M16       RP11-89M16-A\     TTCCCAGCTCGTGCTCTCA\           CAGTGGAAGGCTCTTCATGCT\
                                  RP11-89M16-B\     TGGATGGTGCTAGAGAGGTAGATG\      TGCAGGAATGTGCTGGTTTG\
                                  RP11-89M16-C      CAGGATCACCCAAGGCAGTAA          TCTAAACTCCCTTTTTGAGGCATT
  ---------------------------------------------------------------------------------------------------------------
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